intrahepatic%20cholestasis
INTRAHEPATIC CHOLESTASIS
Cholestasis is bile formation and/or bile flow impairment that manifests as fatigue, pruritus and jaundice.
It can be classified into intrahepatic or extrahepatic cholestasis.
Extrahepatic cholestasis develops from mechanical blockage in the duct system or hepatocellular defects.
Intrahepatic cholestasis may be due to functional defects hepatocellularly or from obstructive lesions of the intrahepatic biliary tract distal from the bile canaliculi.

Intrahepatic%20cholestasis Management

Follow Up

  • In patients with PSC, suspect cholangiocarcinoma if with weight loss, worsening cholestasis, elevated serum level of CA 19-9, and/or new or progressive stricture, especially with an enhancing mass lesion 
  • Follow-up in ICP patients should be long enough to ensure a normalization of LFTs, and it is reasonable to check LFTs at 6 weeks
    • If after 6 months there is no improvement, further specialist input will be required 
  • ICP should settle spontaneously following delivery
  • The outcome of drug-induced cholestasis after withdrawal of the drug is generally good and few patients who develop DILI show abnormal liver tests and persistent histological evidence of liver damage at follow-up
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 4 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
4 days ago
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase the risk for diabetic ketoacidosis (DKA) by almost threefold, with molecule-specific analyses suggesting a class effect, according to a study.
Jairia Dela Cruz, 03 Aug 2020
In the first year following percutaneous coronary intervention for acute coronary syndrome, ticagrelor and prasugrel cuts the risk of gastrointestinal (GI) bleeding by more than 30 percent compared with clopidogrel, as shown in a large real-world study.